Generic Name and Formulations:
Varicella zoster vaccine recombinant, adjuvanted; susp for IM inj after reconstitution (contains 50mcg of recombinant glycoprotein E antigen, 50mcg of monophosphoryl lipid A, and 50mcg of QS-21); per 0.5mL; preservative-free.
Indications for SHINGRIX:
Prevention of herpes zoster (shingles) in adults ≥50yrs of age.
Limitations Of use:
Not for preventing primary varicella infection (chickenpox).
<50yrs: not recommended. Give by IM inj in deltoid region of upper arm. ≥50yrs: one 0.5mL dose at Month 0 followed by second dose anytime between 2–6 months later. Administer immediately upon reconstitution or store refrigerated and use within 6hrs.
<18yrs: not established.
Allergies to any previous Shingrix vaccination.
Review immunization history prior to administration. Have appropriate medical treatment and supervision available to manage allergic reactions. Pregnancy. Nursing mothers.
Immunosuppressants may reduce efficacy of Shingrix. Concomitant inactivated influenza vaccines: see full labeling.
Local reactions (eg, pain, redness, swelling), myalgia, fatigue, headache, shivering, fever, GI symptoms.
To report adverse events, contact VAERS at (800) 822-7967.
Single-dose vials—1, 10 (antigen + adjuvant components)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Transference in the Age of #MeToo: What Counts as Harassment From a Patient?
- Models Derived From Electronic Health Records Effective in Predicting Suicide Risk
- Autonomic Function May Have Directional Effect on Depression
- Predictors of Long-term Medication Adherence in Children With ADHD
- Probiotics Effective in Reducing Rehospitalization for Patients With Mania
- Court-Mandated Substance Abuse Treatment: Exploring the Ethics and Efficacy
- ADHD Treatments
- Pharmacogenetics in Psychiatry: Promising Developments and Potential Pitfalls
- Esketamine Nasal Spray: A New Treatment Possibility for Treatment-Resistant Depression
- Substance Abuse and Primary Psychosis: A Closer Look